Skip to content

Construction of a Portal Hypertension Biobank

Construction of a Biobank for a Specialized Cohort of Portal Hypertension

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07419724
Enrollment
1000
Registered
2026-02-19
Start date
2025-10-16
Completion date
2031-12-31
Last updated
2026-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Variceal Bleeding, Portal Hypertension

Brief summary

Esophageal and gastric variceal bleeding (EGVB) is a severe complication of portal hypertension (PH), characterized by high bleeding volume, high rebleeding rate, and high mortality. In recent years, endoscopic treatment has significantly improved therapeutic efficacy and patient survival. However, due to substantial individual variations among patients, individualized stratified management is crucial. For special populations with cirrhotic portal hypertension, clear management guidelines and clinical research evidence are lacking. The incidence of non-cirrhotic portal hypertension is increasing year by year; it has complex etiologies, lacks specific symptoms and imaging features, and poses diagnostic challenges. Currently, multi-omics research on portal hypertension is insufficient. The integration of multi-omics technologies, including genomics, radiomics, metabolomics, and gut microbiota, holds promise for a more comprehensive understanding of the pathogenesis. With continuous improvements in multi-modal medical data fusion technology, there is an urgent need to develop clinical decision support systems by combining standardized multi-omics databases with artificial intelligence techniques, thereby enhancing clinical decision-making capabilities and prognostic assessment. This study aims to expand the established portal hypertension biobank by extending the temporal depth of clinical cohort data and diversifying sample types.

Interventions

Endoscopic treatment including ligation and cyanoacrylate injection

Sponsors

Shanghai Zhongshan Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Clinically diagnosed with portal hypertension complicated by esophagogastric varices. 2. Underwent abdominal CT examination

Exclusion criteria

1. Imaging or endoscopic evidence demonstrating absence of esophageal and/or gastric varices. 2. CT image quality not meeting requirements or incomplete medical history data.

Design outcomes

Primary

MeasureTime frame
One-year rebleedingWithin 1 year

Secondary

MeasureTime frameDescription
DeathWithin 1 year
ComplicationsWithin 1 yearPortal hypertension-related complications (including ascites, hepatic encephalopathy, portal vein thrombosis, etc.)

Countries

China

Contacts

CONTACTXiaoquan Huang, M.D.
huang.xiaoquan@zs-hospital.sh.cn86-18801733835

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026